Hans-Werner Rausch

Hans-Werner Rausch

Auto-generated profile, based on publicly available information

Hans-Werner Rausch

Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2024 in Nature Aging
Verified
Journal Article
Open access
PDF file
SWSven Wischnewski
Sven Wischnewski
TTThomas Thäwel
Thomas Thäwel
CIChiseko Ikenaga
Chiseko Ikenaga
AKAnna Kocharyan
Anna Kocharyan
CLCelia Lerma-Martin
Celia Lerma-Martin
LSLucas Schirmer
Lucas Schirmer
Inclusion body myositis (IBM) is the most prevalent inflammatory muscle disease in older adults with no effective therapy available. In contrast to other inflammatory myopathies such as subacute, immune-mediated necrotizing myopathy (IMNM), IBM follows a chronic disease course with both inflammatory and degenerative features of pathology. Moreover, causal factors and molecular drivers of IBM progression are largely unknown. Therefore, we paired single-nucleus RNA sequencing with spatial transcriptomics from patient muscle biopsies to map cell-type-specific drivers underlying IBM pathogenesis compared with IMNM muscles and noninflammatory skeletal muscle samples. In IBM muscles, we observed a selective loss of type 2 myonuclei paralleled by increased levels of cytotoxic T and conventional type 1 dendritic cells. IBM myofibers were characterized by either upregulation of cell stress markers featuring GADD45A and NORAD or protein degradation markers including RNF7 associated with p62 aggregates. GADD45A upregulation was preferentially seen in type 2A myofibers associated with severe tissue inflammation. We also noted IBM-specific upregulation of ACHE encoding acetylcholinesterase, which can be regulated by NORAD activity and result in functional denervation of myofibers. Our results provide promising insights into possible mechanisms of myofiber degeneration in IBM and suggest a selective type 2 fiber vulnerability linked to genomic stress and denervation pathways.

11 February 2025 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
SWSven Wischnewski
Sven Wischnewski
HRHans-Werner Rausch
Hans-Werner Rausch
CIChiseko Ikenaga
Chiseko Ikenaga
JLJan Leipe
Jan Leipe
TLThomas E. Lloyd
Thomas E. Lloyd
LSLucas Schirmer
Lucas Schirmer
Idiopathic inflammatory myopathies (IIMs), or myositis, are rare diseases marked by immune-driven muscle damage and complications like skin lesions and interstitial lung disease (ILD). Despite advances, challenges in diagnosis and treatment persist, particularly in inclusion body myositis (IBM), where no effective therapy exists. Recent breakthroughs, including transcriptomics and insights into antibody-mediated immunity and interferon (IFN) signaling, have clarified IIM pathophysiology and spurred the development of new therapies, such as chimeric antigen receptor (CAR) T cells and Janus kinase (JAK) inhibitors. We explore the latest findings on the mechanisms underlying adult-onset IIMs, emphasizing IBM pathobiology and its unique immune and degenerative pathways, such as a selective type 2 myofiber damage and severe cell stress. Finally, we highlight the recent advances in transcriptomics, single-cell analysis, and machine learning in transforming IIM research by improving diagnostic accuracy, uncovering therapeutic targets, and supporting the development of personalized treatment strategies.

8 July 2026 in BMJ Open
Verified
Journal Article
Open access
RRRebekka Rust
Rebekka Rust
SSSara Samadzadeh
Sara Samadzadeh
ARAnna-Lena Röper
Anna-Lena Röper
ASAlexander Stahmann
Alexander Stahmann
PSPatrick Schindler
Patrick Schindler
LBLina Samira Bahr
Lina Samira Bahr
Introduction: Advances in ultrasensitive assay techniques have enabled precise quantification of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP), highlighting their potential as dynamic biomarkers for detecting neuroaxonal injury, disease activity and progression in multiple sclerosis (MS). In the NeuroFilMS study, sNfL is being investigated prospectively as a prognostic biomarker for clinical and radiological disease activity in relapsing MS, while sGFAP is retrospectively explored as a marker of disease progression. The aim is to assess whether longitudinal monitoring of sNfL can inform diagnostic and therapeutic decisions in the treatment of people with MS (pwMS) and whether retrospective sGFAP measurements provide additional insights into disease progression. The study additionally aims to evaluate the comparability of different assay methods. Methods and analysis: NeuroFilMS is a prospective, multicentre study that will be conducted across multiple MS study centres throughout Germany, in collaboration with the German Multiple Sclerosis Registry set up by the German National Multiple Sclerosis Society (Deutsche Multiple Sklerose Gesellschaft). The study aims to enrol 1500 pwMS diagnosed with relapsing MS. Participants will be randomised in a 2:1 ratio (n=1000 vs n=500) to either immediate sNfL reporting or delayed sNfL reporting to treating physicians, in order to evaluate how sNfL availability influences therapeutic decision-making in routine healthcare regarding diagnostics and therapy decisions. Over a 2-year follow-up period, pwMS will attend three study visits integrated into routine care, including blood sampling for sNfL, clinical evaluations and routine MRI assessments; sGFAP will be measured retrospectively in batches, as it is not currently available for routine diagnostic use. The study follows the standardised protocols for biosample collection, performed both within clinical routine laboratory procedures and through research collaboration. Statistical analyses will involve both descriptive and inferential methods to evaluate biomarker performance and clinical associations. Ethics and dissemination: The study has received ethical approval from the Clinical Ethics Committee of Charité–Universitätsmedizin Berlin (EA4/136/24) and will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Findings will be disseminated through peer-reviewed publications, conference presentations and engagement with patient organisations and clinical networks. Trial registration number: DRKS00034337.

1 January 2026
Verified
Book Chapter
Closed access
PDF file
MGMatthias Gasser
Matthias Gasser
TMTheoni Maragkou
Theoni Maragkou
BMBritta Maurer
Britta Maurer
HRHans-Werner Rausch
Hans-Werner Rausch
LSLucas Schirmer
Lucas Schirmer